Collectively, these metabolic data indicate that CAMKK2 inhibition impacts symptoms of metabolic syndrome including sustained improvements in insulin sensitivity in preclinical models of prostate cancer. This evidence concerns the gene CAMKK2 and prostate carcinoma.